Загрузка...
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
BACKGROUND: HER2 mutation has been found to be an oncogenic driver gene in non-small cell lung cancers(NSCLC) and HER2-directed therapies have shown promising results in this unique population, while little is known about its association with outcomes of chemotherapy. The aim of this study was to in...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5869778/ https://ncbi.nlm.nih.gov/pubmed/29587667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4277-x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|